⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376 | 0.69 | — | — | |
| SCHEMBL22361821 | 0.66 | — | — | |
| SCHEMBL21634082 | 0.65 | — | — | |
| SCHEMBL26622107 | 0.65 | — | — | |
| SCHEMBL26622155 | 0.65 | — | — | |
| SCHEMBL21634247 | 0.63 | — | — | |
| SCHEMBL21634037 | 0.63 | — | — | |
| SCHEMBL21634038 | 0.63 | — | — | |
| SCHEMBL9702622 | 0.63 | — | — | |
| SCHEMBL514537 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685585-B | Nucleotide sequence, double-stranded oligonucleotide, pharmaceutical composition and conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-114685585-A | Nucleotide sequence, double-stranded oligonucleotide, pharmaceutical composition and conjugate, and preparation method and application thereof | 苏州瑞博生物技术股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2021-11-11 | — | — | US | disclosed |
| WO-2020236755-A2 | ANGIOTENSIN II TYPE 1 RECEPTOR TARGETED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-3707156-A2 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| WO-2019092618-A9 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2019-05-09 | — | — | US | disclosed |
| EP-3452049-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192820-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-7713944-B2 | Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20060142232-A1 | administering an antisense oligomer conjugate comprises an activated disulfide moiety and a bivalent linking group; capable of forming a bio-reversible bond with a plasma protein; stable under plasma blood conditions and unstable under cellular conditions | IONIS PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-4693742-A | Herbicidal hydroxyamino phosphonic acids and derivatives | ROHM AND HASS COMPANY (US) | 1987-09-15 | — | — | US | disclosed |